A divergent two-step process has provided access to opticallypureenantiomers of MDMA and MDA, clinically relevant phenylisopropylamineentactogens. Target compounds were synthesized from commercially availablealanine-derived aziridines. Critical process parameters were identified,and the reactions were optimized to avoid chromatographic purificationstoward gram-scale isolations, providing (R)-(-)-MDMA,(S)-(+)-MDMA, (R)-(-)-MDA,and (S)-(+)-MDA each in greater than 98% purity byUPLC, >99% enantiomeric excess, and net yields between 50 and 60%for the complete process.